Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9.
Lancet. 2019.
PMID: 31189511
Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators.
Gerstein HC, et al.
Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9.
Lancet. 2019.
PMID: 31189509
Clinical Trial.
At baseline, 791 (7.9%) had macroalbuminuria and mean eGFR was 76.9 mL/min per 1.73 m(2) (SD 22.7). During a median follow-up of 5.4 years (IQR 5.1-5.9) comprising 51 820 person-years, the renal outcome developed in 848 (17.1%) participants at an incidence rate of 3.5 per …
At baseline, 791 (7.9%) had macroalbuminuria and mean eGFR was 76.9 mL/min per 1.73 m(2) (SD 22.7). During a median follow-up of 5.4 …
Item in Clipboard
Cite
Cite